<?xml version="1.0" encoding="UTF-8"?>
<p>The present study evaluated the efficacy of preoperative DCS therapy. The primary endpoint was the pathological response rate (pRR), and the secondary endpoints were chemotherapy-related toxicities, morbidity and mortality as short-term outcomes and the overall and relapse-free survival as long-term outcomes. This report clarified the impact of DCS on short-term endpoints.</p>
